Cerevance
Cerevance is a biotechnology company that develops novel therapeutics for neurological diseases, including chronic neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Using a large and growing repository of over 15,000 human brain tissue samples, the company generates an unprecedented level of expression and epigenetic data, enabling the company to identify the most promising targets for the next generation of treatments for CNS disorders.
Cerevance
Cerevance is a biotechnology company that develops novel therapeutics for neurological diseases, including chronic neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Using a large and growing repository of over 15,000 human brain tissue samples, the company generates an unprecedented level of expression and epigenetic data, enabling the company to identify the most promising targets for the next generation of treatments for CNS disorders.
TL;DR
Stage: Clinical-stage biotechnology
Focus: Precision therapeutics for CNS disorders (Alzheimer's, Parkinson's, FTD, ALS)
Platform: NETSseq human post-mortem brain transcriptional and epigenetic profiling
Lead program: CVN424 (GPR6-targeting, non-dopaminergic Parkinson's candidate)
Notable funding: Series B activity including closes in 2020, 2023 and a Series B-1 extension in 2024; cumulative funding reported ~$189.5M
Company Overview
Problem Domain
Neurological and neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, frontotemporal dementia, amyotrophic lateral sclerosis)
Founded
2016
Industry
Biotechnology / Biopharmaceuticals
Tech Stack
Funding Track Record
36000000.00
Initial financing at launch reported as approximately $36M, including Takeda and Lightstone participation.
45000000.00
Series B close reported April 14, 2020 (~$45M); investors included GV, Gates, Foresite Capital and returning investors.
51000000.00
Additional $51M close bringing Series B financing to $116M.
47000000.00
Initial closing of a Series B-1 extension adding $47M.
Investor Signal
“Participation from strategic and prominent life-science investors including Takeda Ventures, Lightstone Ventures, GV (formerly Google Ventures), Gates Frontier/Gates family investors, Foresite Capital, Dementia Discovery Fund and others”